NOTV (NOTV)
AI stock analysis · as of Jun 13, 2026
Loading microstructure…
Inotiv (NOTV) is a contract research organization serving pharma and medical device clients through Discovery & Safety Assessment (DSA) and Research Models & Services (RMS) segments. The company filed Chapter 11 bankruptcy in June 2026 to restructure $326M+ in debt, with the reorganization plan explicitly canceling existing equity. The 'investment question' is essentially moot: at $0.08 with shares delisted and a court-approved wipeout pending, this is a distressed equity stub trading on speculative bankruptcy-bounce dynamics, not on fundamental value.
valuationNot meaningfully valuable as equity: P/S of 0.005x and P/B of 0.036x reflect a market pricing in near-total wipeout; forward P/E negative; EV/EBITDA of 55x is misleading given debt dominates enterprise value and equity is a residual call option on a zero-recovery outcome.
This analysis is from Jun 13, 2026. Want the latest on NOTV, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Operating businesses have value: DSA service revenue grew 3.4% YoY in Q2 FY26 and 7.1% over six months, and DSA segment operating income was $14.3M — the underlying CRO franchise is viable and will likely emerge intact under new ownership
- · DIP financing of $65.5M secured, ensuring operational continuity through restructuring; creditors evidently see going-concern value
- · Short interest at 7.86% of float with 3.16 days to cover provides some squeeze potential on any positive headline (e.g., unexpected equity recovery in plan amendments)
- · Price-to-sales of 0.005x and price-to-book of 0.036x reflect total distress pricing — any non-zero recovery for equity would be a multi-bagger from $0.08
- · No insider net selling in last 180 days per data (though prior CEO sale flagged in news)
Bear case
- · Chapter 11 plan explicitly cancels existing equity — current shareholders are expected to be wiped to zero, which is the modal outcome
- · $416M total debt all classified current against only $15.2M cash; equity eroded from $136M to $77M in six months and is rapidly approaching negative
- · Stock has been delisted from Nasdaq and removed from major indices, severely impairing liquidity and institutional ownership viability (institutions only 14%)
- · Net loss widened to $60.8M for six months vs $42.5M prior year; operating loss nearly doubled to -$35.6M; FCF -$27M with $27.5M of semi-annual interest expense alone
- · RMS segment revenue collapsing -10.7% YoY in Q2, with RMS operating income falling from $25.0M to $16.2M — the non-DSA half of the business is deteriorating
- · Debt-to-equity of 632x and ROE of -74% reflect a balance sheet that mathematically cannot support equity value
- · News sentiment -0.82; reported CEO share sale in February ahead of the collapse signals insider conviction was already gone
Catalysts
- · Bankruptcy plan confirmation hearing — will formalize equity cancellation if approved as currently structured
- · Any disclosure statement amendments that hint at a small equity recovery pool or warrants for existing holders (low probability)
- · Short squeeze potential given 7.86% short float and delisted/illiquid trading — sharp spikes possible but not fundamentally supported
- · Court rulings on creditor objections or competing reorganization proposals
- · Resolution of DOJ fines and securities class action could marginally affect recovery waterfall
Key risks
- · Equity cancellation under confirmed plan of reorganization — primary and overwhelming risk
- · Further delisting/OTC pink sheet illiquidity making exit impossible at any price
- · Cross-default cascade if grace periods lapse without resolution
- · Customer attrition during bankruptcy (one client = 15.2% of revenue) could impair reorganized enterprise value, eliminating any residual equity recovery scenario
- · Continued cash burn (-$6.5M operating outflow in 6 months) exhausts DIP financing before emergence
What to watch
- · Plan confirmation hearing date and any disclosure statement amendments mentioning equity treatment
- · Court docket for creditor committee objections or equity committee formation requests
- · DIP financing covenants and milestones — any breach accelerates timeline to confirmation
- · OTC trading volume and short interest changes for squeeze risk monitoring
- · Next earnings date 2026-08-05 (likely superseded by bankruptcy disclosures)
- · Key price level: $0.08 (52-week low) — break below confirms market consensus of zero recovery
Key metrics
Price target rationale
Base case $0.00: the reorganization plan explicitly cancels existing equity, which is the standard and expected outcome. Bull case $0.25 reflects a low-probability scenario where holders receive token warrants or a small recovery pool in plan negotiations, or sustained squeeze dynamics on the delisted stub. Bear case $0.00 on plan confirmation. No defensible multiple-based target exists given equity is structurally subordinated to $416M in claims against ~$77M (and falling) of book equity.
On Wall Street's view (disagree): The 'strong_buy' recommendation appears stale and predates the Chapter 11 filing and explicit equity cancellation language; no analyst price targets are available, and the last downgrade dates to May 2024. Any nominal buy rating is disconnected from current bankruptcy reality.
Latest filing (10-Q)
Inotiv is a CRO in acute financial distress — $416M in debt all due within 12 months, only $15M cash, a missed bond interest payment that could trigger cross-default on all debt by May 15, 2026, and management openly warning of going concern doubt while scrambling for a rescue transaction.
Inotiv, Inc. (NOTV) is a contract research organization (CRO) providing nonclinical drug discovery and safety assessment services to pharmaceutical and biotech companies, and selling research-quality animals, diets, and related products to biopharma, academic, and government clients. Revenue is split roughly evenly between services (DSA segment: drug discovery/safety testing) and products (RMS segment: research animal models, diets, bedding). The company operates primarily in the US and Netherlands.
What the news says · bearish
Inotiv's dominant storyline is a full-blown financial collapse: the company filed for Chapter 11 bankruptcy in early June 2026 to restructure $326M in debt, with the reorganization plan explicitly canceling existing equity — meaning current shareholders are expected to be wiped out. The stock was delisted from Nasdaq and dropped from major indices, and while shares briefly spiked post-filing (a common but misleading bankruptcy bounce), the DIP financing and restructuring are designed to benefit creditors, not equity holders. Earlier warning signs were abundant — a CEO share sale in February, covenant waivers in April, missed interest payments, and $40M in emergency bridge debt in May — all pointing to an inevitable restructuring. Any bullish price action seen in April or around the filing should be treated with extreme caution given the explicit equity cancellation language in the plan.
This analysis is from Jun 13, 2026. Markets move. Get the current read on NOTV and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.